Results 1 to 10 of about 8,718 (117)
Hematopoietic stem cell transplantation
Stem Cells and Cloning: Advances and Applications, 2010 Eleftheria Hatzimichael1, Mark Tuthill21Department of Haematology, Medical School of Ioannina, University of Ioannina, Ioannina, Greece; 2Department of Medical Oncology, Hammersmith Hospital, Imperial College National Health Service Trust, London ...
Eleftheria Hatzimichael, Mark Tuthill
doaj +5 more sources
BMC Medical Genomics, 2022 Background Acute lymphoblastic leukemia (ALL) is a type of heterogeneous hematopoietic malignancy that accounts for approximately 20% of adult ALL. Although ALL complete remission (CR) rate has increased to 85–90% after induction chemotherapy, 40–50% of ...
Xin Zong +7 more
doaj +1 more source
Hematology, 2022 Objective To explore the efficacy and safety of thrombopoietin receptor agonists (TPO-RAs) without anti-thymocyte globulin (ATG) in ATG-naïve patients with aplastic anemia (AA) in a real-world setting.Methods We retrospectively evaluated treatment ...
Masaki Iino +3 more
doaj +1 more source
Mesenchymal stem cells in hematopoietic stem cell transplantation [PDF]
Cytotherapy, 2009 Mesenchymal stromal/stem cells (MSC) of bone marrow (BM) origin not only provide the supportive microenvironmental niche for hematopoietic stem cells (HSC) but are capable of differentiating into various cell types of mesenchymal origin, such as bone, fat and cartilage.
Minoo, Battiwalla, Peiman, Hematti
openaire +2 more sources
Identification of a novel HOOK3-FGFR1 fusion gene involved in activation of the NF-kappaB pathway
Cancer Cell International, 2022 Background Rearrangements involving the fibroblast growth factor receptor 1 (FGFR1) gene result in 8p11 myeloproliferative syndrome (EMS), which is a rare and aggressive hematological malignancy that is often initially diagnosed as myelodysplastic ...
Xuehong Zhang +10 more
doaj +1 more source
Hematopoietic stem cell transplantation in Egypt [PDF]
Bone Marrow Transplantation, 2008 Hematopoietic SCT is now an established treatment modality with definitive indications for many hematological disorders. However, this line of treatment requires tremendous resources, and it becomes increasingly difficult for transplanters practicing in the developing world to reconcile the difference between what is possible and what is available.
Hk, Mahmoud +7 more
openaire +2 more sources
Biomolecules & Biomedicine, 2023 Quantification of measurable residual disease (MRD) correlates with the risk of leukemia recurrence in adults with B-cell acute lymphoblastic leukemia (ALL).
Lei-Ming Cao +16 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Hepatocellular carcinoma (HCC) is the most prevalent subtype of liver cancer with a mortality rate of approximately 3–6/100,000 and is the third leading cause of cancer-related death worldwide.
Haina Wang +13 more
doaj +1 more source
Hematopoietic stem cell transplantation in thalassemia [PDF]
Bone Marrow Transplantation, 2008 SCT still remains the only cure currently available for patients with thalassemia. Results of transplants in this disease have steadily improved over the last two decades due to improvements in preventive strategies, effective control of transplant-related complications and development of new preparative regimens.
J, Gaziev, P, Sodani, G, Lucarelli
openaire +2 more sources
Journal of Hematology & Oncology, 2017 Background The optimal monitoring schedules and cutoff minimal residual disease (MRD) levels for the accurate prediction of relapse at all time points after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients with t ...
Ya-Zhen Qin +14 more
doaj +1 more source